For the quarter ending June 30 2023, PULSE BIOSCIENCES ($NASDAQ:PLSE) reported a 100.0% year-over-year decline in total revenue to USD 0.0 million and a net income of USD -9.9 million, better than the -14.0 million reported for the same quarter of the previous year. The results were announced on August 10 2023.
Analysis – Pulse Biosciences Intrinsic Value Calculator
GoodWhale has conducted an in-depth analysis of PULSE BIOSCIENCES‘s financials and has calculated the intrinsic value of its shares to be around $13.2, using our proprietary Valuation Line. This implies that the current stock price of PULSE BIOSCIENCES, which is at $6.8, is undervalued by 48.4%. This presents an opportunity for investors to buy PULSE BIOSCIENCES stock at an attractive price. GoodWhale has a long and successful track record in offering reliable and accurate financial insights to investors. Our Valuation Line has been developed after extensive research and analysis of a wide range of companies and industries. It is designed to provide a precise understanding of the intrinsic value of a share and to identify undervalued stocks providing a great investment opportunity. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pulse Biosciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pulse Biosciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pulse Biosciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pulse Biosciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
It competes in the space with Verisante Technology Inc, CVRx Inc, and Motus GI Holdings Inc. All four companies are working towards the common goal of providing innovative healthcare solutions to improve outcomes for patients.
– Verisante Technology Inc ($TSXV:VER.H)
Verisante Technology Inc is a medical technology company focused on developing and commercializing cancer detection systems. With a market cap of 491.07k as of 2023, the company has seen significant growth in its value over the years. This is further supported by a Return on Equity of 611.43%, indicating that the company is making effective use of its resources to generate returns for its shareholders. Verisante offers a range of products that are designed to help detect and diagnose various types of cancer in an early stage, in order to improve patient outcomes.
CVRx Inc. is a medical device company focused on providing innovative treatments for cardiovascular disease. The company has a market capitalization of 274.42 million as of 2023 and a Return on Equity of -25.31%. Market cap is calculated by multiplying the company’s share price by the number of shares in circulation and is used to measure the size of a company. A negative return on equity indicates that the company is not generating enough income from its resources. This could be due to poor management or a lack of access to resources. CVRx Inc is actively seeking new treatments for cardiovascular diseases, which could lead to an improved return on equity in the future.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a medical technology company that focuses on the development of technologies that reduce the costs and improve the outcomes of colonoscopy procedures. Its market cap as of 2023 currently stands at 3.87M, which is significantly lower than the industry average. Its Return on Equity (ROE) is -1124.01%, which again is significantly lower than the industry average. This means that Motus GI Holdings Inc is not generating a positive return on its shareholders’ investments. Despite this, the company has continued to develop innovative technologies that have the promise of reducing costs and improving outcomes for its customers. As such, it is likely that its market cap and ROE will eventually increase in the near future.
Investors of Pulse Biosciences have recently been analyzing the company’s financials for the quarter ending June 30, 2023. The company reported total revenue of USD 0.0 million, a 100.0% decrease year over year, and a net income of USD -9.9 million, compared to -14.0 million in the same quarter of the previous year. As a result, the stock price reacted accordingly with a downward trend on August 10, 2023.
Such developments paint a negative outlook for Pulse Biosciences, making it a riskier investment in its current state. Investors should closely monitor the company’s future performance to assess its financial standing.